Blood Pressure Variability in Fabry Disease Patients

Nephron. 2022;146(4):343-350. doi: 10.1159/000520699. Epub 2021 Dec 21.

Abstract

Introduction: Fabry disease is a rare metabolic, multisystemic, and X-linked lysosomal storage disorder. The involvement of the autonomic nervous system is well defined; however, data on the variability of the blood pressure (BP) and heart rate in Fabry disease are largely missing. In this study, we aimed to examine the circadian variations of BP and heart rate variability in Fabry disease patients.

Methods: We recruited 31 consecutive adult (age >18 years) Fabry disease patients (16 males and 15 females) who were regularly followed up in our outpatient clinic between July 2019 and March 2020. We performed ambulatory blood pressure monitoring and echocardiography in all patients. We used standard deviation (SD), coefficient of variation (CV), and average real variability as the measures of variability. We constructed 2 control groups for propensity score matching using age, sex, and eGFR parameters in the first group and adding antihypertensive drug use to the above parameters in the second group.

Results: All BP measurements were significantly lower in the FD group compared to that of the control groups, except the nighttime systolic BP. Regarding nondipping and reverse dipping statuses, FD patients and controls were similar. We found that none of the BP variability measures were higher in FD patients. Regarding heart rate variability data, both the nighttime SD and CV were significantly lower in FD patients compared to those of the controls.

Conclusion: A decrease in heart rate variability, rather than an increase in BP variability, might be an early marker of autonomic involvement in FD.

Keywords: Ambulatory blood pressure monitoring; Blood pressure; Fabry disease.

MeSH terms

  • Adolescent
  • Adult
  • Antihypertensive Agents / therapeutic use
  • Blood Pressure
  • Blood Pressure Monitoring, Ambulatory
  • Circadian Rhythm / physiology
  • Fabry Disease* / complications
  • Fabry Disease* / drug therapy
  • Female
  • Heart Rate
  • Humans
  • Hypertension* / drug therapy
  • Male

Substances

  • Antihypertensive Agents